Author

A. Kuenkele

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

A. Pruss· 2 shared D. L. Wagner· 2 shared H.-D. Volk· 2 shared J. Kath· 2 shared L. Andersch· 2 shared M. Schmueck-Henneresse· 2 shared M. Stein· 2 shared P. Reinke· 2 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Pruss

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

L. Grunewald, L. Andersch, K. Helmsauer, S. Schwiebert, A. Klaus, A. G. Henssen, T. Straka, M. Lodrini, S. G. Wicha, S. Fuchs, F. Hertwig, F. Westermann, A. Vitali, C. Caramel, G. Buechel, , A. Kuenkele

This paper shows that high MYCN levels in neuroblastoma reduce L1CAM expression, limiting CAR T cell efficacy, and that inhibiting MYCN with MLN8237 restores L1CAM and enhances CAR T cell activity.

bioRxiv · Jan 27, 2024Immunology

Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells

J. Kath, C. Franke, V. Drosdek, W. Du, V. Glaser, C. Fuster-Garcia, M. Stein, T. Zittel, S. Schulenberg, C. E. Porter, L. Andersch, A. Kuenkele, J. Alcaniz, J. Hoffmann, H. Abken, , D. L. Wagner

This paper develops a method to integrate ζ-deficient CARs into the CD3ζ gene to create functional CAR-T and CAR-NK cells with improved safety and efficacy for off-the-shelf therapies.

bioRxiv · Nov 10, 2023 · PreprintImmunology

Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma

T. L. B. Hoelting, F. Cidre-Aranaz, D. Matzek, B. Popper, S. J. Jacobi, J. Li, I. Piseddu, B. L. Cadilha, S. Ledderose, J. Zwilling, S. Ohmura, D. Anz, A. Kuenkele, F. Klauschen, T. G. P. Gruenewald, M. M. L. Knott

This paper develops a gene expression strategy that exploits neomorphic DNA-binding of fusion transcription factors in pediatric sarcomas to deliver therapeutic payloads with tumor-specific efficacy.

bioRxiv · Jan 5, 2022Cancer Biology

Fast, efficient and virus-free generation of TRAC-replaced CAR T cells

J. Kath, W. Du, B. Thommandru, R. Turk, L. Amini, M. Stein, T. Zittel, S. Martini, L. Ostendorf, A. Wilhelm, L. Akyuez, A. Rehm, U. E. Hoepken, A. Pruss, A. Kuenkele, , D. L. Wagner

This paper presents a virus-free method to generate CAR T cells by inserting CARs into the TRAC locus using CRISPR-Cas and HDR, achieving up to 68% TCR-to-CAR replacement.

bioRxiv · Feb 14, 2021Immunology